Pfizer Inc. announced today that it will present data for several of its marketed and investigational medicines for inflammatory and immunological conditions at the American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) 2014 Annual Meeting (November 14-19, Boston, Massachusetts). Twenty-one abstracts for XELJANZ® (tofacitinib citrate) will be presented, including the six-year safety and efficacy analyses from long-term extension (LTE) studies and a summary of real-world patient experience, additional post-hoc analyses from the clinical development program, and health and economics outcomes research, adding to the substantial body of evidence for XELJANZ as an oral treatment option for moderate to severe rheumatoid arthritis (RA).
Help employers find you! Check out all the jobs and post your resume.
